key: cord-1010960-hybxu21t authors: Farrugia, Albert; MacPherson, Jim; Busch, Michael P. title: Convalescent plasma – this is no time for competition date: 2020-06-25 journal: Transfusion DOI: 10.1111/trf.15922 sha: 4463c31b01013c2f233b2861d66c203fb2fad5ce doc_id: 1010960 cord_uid: hybxu21t nan As of May 30, 2020, a randomized trial for the use of remdesivir in patients with severe coronavirus disease 2019 has provided the only first-level evidence of efficacy in this infection, albeit with modest results. 1 The other therapeutic modality reported to affect mortality in patients suffering from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the transfusion of plasma collected from donors who have recovered from the infection (convalescent plasma [CP]). Small observational studies in China [2] [3] [4] ; larger studies in the United States, 5,6 including a study employing matched controls; 7 and a proof-of-concept study in Italy 8 have delivered promising results, while randomized trials have been proposed 9 or are under way. 10, 11 In tandem with the collection of CP for therapeutic use, 12 efforts are under way to collect plasma for manufacture into an immunoglobulin preparation rich in antibodies to SARS-CoV-2 (hyperimmune immunoglobulin [IG]), similar to other IGs used for prophylaxis against infections such as tetanus, hepatitis B, and other pathogens. 13 These efforts by the companies of the plasma therapeutics industry, most of whom have formed an umbrella "Plasma Alliance" to maximize plasma collection and the development of an IG. 14 While several hyperimmune IGs are effective in prophylaxis against infectious agents, the use of these products for the treatment of infections is less well established. In recent years, only plasma-derived polyclonal IG against respiratory syncytial virus has been used therapeutically, 15 until replaced by a monoclonal antibody product. 16 Reservations exist regarding the evidence base for the efficacy of both of these therapies. 17 The efficacy of manufactured IG may be influenced by changes induced in the immunoglobulin G (IgG) subclass composition of these products by the plasma fractionation process. Changes of this kind have been reported for other IGs, and IgG3 has been shown to be particularly susceptible to depletion during fractionation. 18, 19 IgG3 shows selectively enhanced potency against certain pathogens in polyclonal IGs, 20 as well as forming a substantial proportion of the neutralizing antibodies to SARS-CoV-2 generated during the infection. 21 Hence, extensive preclinical and clinical development of any anti-SARS-CoV-2 IG will be required to ensure therapeutic efficacy and equivalence to the antibody profile and clinical properties of CP. We are therefore concerned by media reports of evolving competition for plasma donors between the two sectors collecting CP as outlined above. 22 We apprehend that potential CP donors who may approach the community blood sector for altruistic reasons may be deflected to the commercial sector through the high remuneration offered. 22 This may be accentuated during this period as the traditionally low-resource population of paid plasma donors 23 may be further augmented through the difficult economic situation, as occurred in previous economic crises. 24, 25 We propose that during the current phase of the epidemic, when 1000 of patients may benefit from CP transfusion, such a development may be detrimental to the public health. Given the previous history of hyperimmune IG, anti-SARS-CoV-2 IG may be limited to prophylaxis of groups at high risk of infection, rather than effective for treatment of patients with COVID-19 at different stages of clinical disease progression. Such a product should also be stocked in preparation for subsequent waves of the infection, particularly in the event that an efficacious prophylactic vaccine may not be widely available. The best way forward, it seems, would be that national healthcare systems implement a structured and transparent policy that ensures continued collection and availability of therapeutic CP, coupled with a measured and regulated pace in the collection of plasma hyperimmune IG manufacturers require to validate their processes and fully characterize their products. Remdesivir for 5 or 10days in patients with severe Covid-19 Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest [serial online Treatment of COVID-19 patients with convalescent plasma in Houston, Texas. medRxiv Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. med-Rxiv Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial Plasma: National study from the National Institute for Health and the Italian Agency for pharmacesuticals Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 Convalescent plasma COVID-19 (Coronavirus) treatment -Mayo Clinic Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection Characterization of antibodies to capsular polysaccharide antigens of haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations Measles-virusneutralizing antibodies in intravenous immunoglobulins Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1 Rapid generation of neutralizing antibody responses in COVID-19 patients. medRxiv Market for blood plasma from COVID-19 survivors heats up Society for Social Work and Research 23rd Annual Conference -Ending Gender Based, Family and Community Violence CSL expecting "lumpy" 2021, plasma donation uncertainty Blood Collections & Transfusion: A Global Perspective